TXG vs. CRSP

Last updated Jun 24, 2026

TXG (10x Genomics, Inc.) and CRSP (CRISPR Therapeutics AG) are both stocks. Both are in the Healthcare sector — TXG in Health Information Services, CRSP in Biotechnology. Over the past 5 years, TXG returned -30.33%/yr vs -17.10%/yr for CRSP. At a 0.47 correlation, their price movements are largely independent.

Performance

TXG vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TXG achieves a 95.40% return, which is significantly higher than CRSP's 2.96% return.

TXG

• 1D: -3.25%
• 1M: 34.59%
• YTD: 95.40%
• 6M: 93.15%
• 1Y: 195.37%
• 3Y*: -16.44%
• 5Y*: -30.33%
• 10Y*: —

CRSP

• 1D: -0.68%
• 1M: 7.21%
• YTD: 2.96%
• 6M: -4.37%
• 1Y: 18.53%
• 3Y*: -1.23%
• 5Y*: -17.10%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TXG vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
TXG 10x Genomics, Inc.	95.40%	13.58%	-74.34%	53.57%	-75.54%	5.20%	85.70%	41.20%
CRSP CRISPR Therapeutics AG	2.96%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	27.23%

Correlation

The correlation between TXG and CRSP is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.43
Correlation (5Y) Calculated over the trailing 5-year period	0.48
Correlation (All Time) Calculated using the full available price history since Sep 12, 2019	0.47

The correlation between TXG and CRSP shifts across timeframes, from 0.35 (1 year) to 0.48 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap TXG : $4.09B CRSP : $5.19B
EPS TXG : -$0.18 CRSP : -$6.24
PS Ratio TXG : 6.30 CRSP : 1.20K
PB Ratio TXG : 5.02 CRSP : 2.86
Total Revenue (TTM) TXG : $638.78M CRSP : $4.10M
Gross Profit (TTM) TXG : $444.61M CRSP : -$171.17M
EBITDA (TTM) TXG : -$5.89M CRSP : -$509.21M

Return for Risk

TXG vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TXG

TXG Risk / Return Rank: 93
TXG Sharpe Ratio Rank: 95
TXG Sortino Ratio Rank: 92
TXG Omega Ratio Rank: 87
TXG Calmar Ratio Rank: 96
TXG Martin Ratio Rank: 94

CRSP

CRSP Risk / Return Rank: 52
CRSP Sharpe Ratio Rank: 53
CRSP Sortino Ratio Rank: 54
CRSP Omega Ratio Rank: 51
CRSP Calmar Ratio Rank: 53
CRSP Martin Ratio Rank: 51

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TXG vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	TXG	CRSP	Difference
Sharpe ratio: Return per unit of total volatility	2.85	0.30	+2.55
Sortino ratio: Return per unit of downside risk	3.32	0.90	+2.42
Omega ratio: Gain probability vs. loss probability	1.37	1.10	+0.27
Calmar ratio: Return relative to maximum drawdown	7.02	0.44	+6.58
Martin ratio: Return relative to average drawdown	15.95	0.72	+15.23

TXG vs. CRSP - Sharpe Ratio Comparison

The current TXG Sharpe Ratio is 2.85, which is higher than the CRSP Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of TXG and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

TXG vs. CRSP - Drawdown Comparison

The maximum TXG drawdown since its inception was -96.47%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for TXG and CRSP.

Drawdown Indicators

	TXG	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-96.47%	-85.11%	-11.36%
Max Drawdown (1Y) Largest decline over 1 year	-28.03%	-42.25%	+14.22%
Max Drawdown (3Y) Largest decline over 3 years	-88.66%	-64.91%	-23.75%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	-80.68%	-15.77%
Current Drawdown Current decline from peak	-84.25%	-74.30%	-9.95%
Average Drawdown Average peak-to-trough decline	-59.80%	-49.30%	-10.50%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.30%	25.94%	-13.64%

Volatility

TXG vs. CRSP - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 23.90% compared to CRISPR Therapeutics AG (CRSP) at 17.81%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TXG	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.90%	17.81%	+6.09%
Volatility (6M) Calculated over the trailing 6-month period	48.37%	43.95%	+4.42%
Volatility (1Y) Calculated over the trailing 1-year period	69.03%	62.58%	+6.45%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.75%	60.72%	+8.03%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	66.89%	64.30%	+2.59%

Dividends

TXG vs. CRSP - Dividend Comparison

Neither TXG nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both TXG and CRSP in my portfolio?

TXG and CRSP have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TXG or CRSP?

TXG has higher volatility (23.90%) compared to CRSP (17.81%). In terms of maximum drawdown, TXG dropped -96.47% vs CRSP's -85.11%.

Which has better risk-adjusted returns?

TXG currently has the higher Sharpe Ratio (2.85 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.